We propose to develop a novel method for the delivery of gene-engineered proteins to tumors by targeting the proteins to the granules of tumor infiltrating lymphocytes (TIL). The method is designed to increase tumor selectivity by taking advantage of the granule-release mechanisms that are triggered by specific interactions of lymphocytes with their targets. We have shown in preliminary studies that small transgenic human peptide defensin HNP-1. is targeted to granules of murine granulocytes and cytotoxic T-lymphocytes. Deletion mutagenesis of HNP-1 suggests that a limited segment of this small peptide is essential for granule targeting. In this project we will apply and extend these studies to human TIL with the aim of identifying a peptide sequence, the """"""""targeting motif"""""""", that can direct other gene-engineered proteins to granules. We will first study the expression and subcellular distribution of defensin HNP-1 engineered into human TIL. We will then employ deletion mutagenesis and reporter fusion constructs to characterize the defensin targeting motif and its ability to direct reporter proteins (CAT. IL-8) into granules of TIL. Finally, we will examine the effect of the granule environment on the bioactivity of the reporter proteins and compare the selectivity of reporter protein release by granule-targeted and non-targeted TIL in vitro and in vivo, in human tumor-bearing SCID mice. Successful completion of this project will facilitate future clinical trials of tumor-selective delivery by TIL of therapeutic proteins or immunostimulatory cytokines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059326-04
Application #
5209284
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1996
Total Cost
Indirect Cost
Chen, R L; Reynolds, C P; Seeger, R C (2000) Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother 48:603-12
Penichet, M L; Challita, P M; Shin, S U et al. (1999) In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 49:179-88
Kutubuddin, M; Federoff, H J; Challita-Eid, P M et al. (1999) Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93:643-54
Shau, H; Huang, A C; Faris, M et al. (1998) Thioredoxin peroxidase (natural killer enhancing factor) regulation of activator protein-1 function in endothelial cells. Biochem Biophys Res Commun 249:683-6
Challita-Eid, P M; Penichet, M L; Shin, S U et al. (1998) A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol 160:3419-26
Challita-Eid, P M; Abboud, C N; Morrison, S L et al. (1998) A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol 161:3729-36
Shau, H; Kim, A T; Hedrick, C C et al. (1997) Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses. Free Radic Biol Med 22:497-507
Kim, A T; Sarafian, T A; Shau, H (1997) Characterization of antioxidant properties of natural killer-enhancing factor-B and induction of its expression by hydrogen peroxide. Toxicol Appl Pharmacol 147:135-42
Syljuasen, R G; Belldegrun, A; Tso, C L et al. (1997) Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection. Radiat Res 148:443-8
Arthur, J F; Butterfield, L H; Roth, M D et al. (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17-25

Showing the most recent 10 out of 31 publications